Agilent Technologies
A · Life Sciences Tools & Services
$173.07
0.5%IQVIA
IQV · Life Sciences Tools & Services
$279.36
0.4%The short version
- IQVIA is the larger business, with $16.3B of revenue in fiscal 2025 against $6.9B for Agilent Technologies, about 2.3 times as much.
- Agilent Technologies grew revenue faster (6.7%, against 5.9%).
- Agilent Technologies kept more of each dollar of sales as operating profit (21.3% operating margin, against 13.4% operating margin).
- Agilent Technologies turned more of its sales into free cash flow (16.6% FCF margin, against 12.6% FCF margin).
- Agilent Technologies earned a higher return on the capital invested in it (16.5%, against 9.5%).
- Investors pay more for each dollar of IQVIA’s earnings: a P/E of 34.7x against 34.1x for Agilent Technologies.
| Latest fiscal year | A · FY25 | IQV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $49.0B | $47.4B |
| Revenue | $6.9B | $16.3B |
| Free cash flow | $1.2B | $2.1B |
| Net income | $1.3B | $1.4B |
| Growth | ||
| Revenue growth | 6.7% | 5.9% |
| 5-year growth | 5.4% | 7.5% |
| Share count change | −2.1% | −5.4% |
| Profitability | ||
| Gross margin | 52.4% | — |
| Operating margin | 21.3% | 13.4% |
| Net margin | 18.8% | 8.3% |
| FCF margin | 16.6% | 12.6% |
| Return on capital | 16.5% | 9.5% |
| Return on equity | 20.6% | 21.6% |
| Balance sheet | ||
| Net debt | $1.6B | $13.8B |
| Net debt / EBITDA | 0.9x | 4.2x |
| Dividends and buybacks | $707M | $1.2B |
| Valuation & quality | ||
| P/E | 34.1x | 34.7x |
| Piotroski F-score | 5 | 5 |
FY16
A $4.2B
IQV $6.9B
FY17
A $4.5B
IQV $9.7B
FY18
A $4.9B
IQV $10.4B
FY19
A $5.2B
IQV $11.1B
FY20
A $5.3B
IQV $11.4B
FY21
A $6.3B
IQV $13.9B
FY22
A $6.8B
IQV $14.4B
FY23
A $6.8B
IQV $15.0B
FY24
A $6.5B
IQV $15.4B
FY25
A $6.9B
IQV $16.3B
A
IQV
FY16
A 14.6%
IQV 8.4%
FY17
A 18.1%
IQV 6.8%
FY18
A 18.4%
IQV 7.1%
FY19
A 18.2%
IQV 7.0%
FY20
A 15.9%
IQV 6.4%
FY21
A 21.3%
IQV 10.0%
FY22
A 23.6%
IQV 12.5%
FY23
A 19.8%
IQV 13.2%
FY24
A 22.9%
IQV 14.3%
FY25
A 21.3%
IQV 13.4%
A
IQV
FY16
A $654M
IQV $696M
FY17
A $713M
IQV $601M
FY18
A $910M
IQV $795M
FY19
A $866M
IQV $835M
FY20
A $802M
IQV $1.3B
FY21
A $1.3B
IQV $2.3B
FY22
A $1.0B
IQV $1.6B
FY23
A $1.5B
IQV $1.5B
FY24
A $1.4B
IQV $2.1B
FY25
A $1.2B
IQV $2.1B
A
IQV
FY16
A 14.5%
IQV 3.6%
FY17
A 17.7%
IQV 4.1%
FY18
A 10.9%
IQV 3.5%
FY19
A 19.0%
IQV 3.1%
FY20
A 12.5%
IQV 3.5%
FY21
A 19.3%
IQV 7.0%
FY22
A 19.8%
IQV 8.5%
FY23
A 17.9%
IQV 10.2%
FY24
A 16.9%
IQV 9.8%
FY25
A 16.5%
IQV 9.5%
A
IQV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.